Literature DB >> 20431039

FGF23 fails to inhibit uremic parathyroid glands.

Rocío Canalejo1, Antonio Canalejo, Julio Manuel Martinez-Moreno, M Encarnacion Rodriguez-Ortiz, Jose C Estepa, Francisco Javier Mendoza, Juan Rafael Munoz-Castaneda, Victoria Shalhoub, Yolanda Almaden, Mariano Rodriguez.   

Abstract

Fibroblast growth factor 23 (FGF23) modulates mineral metabolism by promoting phosphaturia and decreasing the production of 1,25-dihydroxyvitamin D(3). FGF23 decreases parathyroid hormone (PTH) mRNA and secretion, but despite a marked elevation in FGF23 in uremia, PTH production increases. Here, we investigated the effect of FGF23 on parathyroid function in normal and uremic hyperplastic parathyroid glands in rats. In normal parathyroid glands, FGF23 decreased PTH production, increased expression of both the parathyroid calcium-sensing receptor and the vitamin D receptor, and reduced cell proliferation. Furthermore, FGF23 induced phosphorylation of extracellular signal-regulated kinase 1/2, which mediates the action of FGF23. In contrast, in hyperplastic parathyroid glands, FGF23 did not reduce PTH production, did not affect expression of the calcium-sensing receptor or vitamin D receptor, and did not affect cell proliferation. In addition, FGF23 failed to activate the extracellular signal-regulated kinase 1/2-mitogen-activated protein kinase pathway in hyperplastic parathyroid glands. We observed very low expression of the FGF23 receptor 1 and the co-receptor Klotho in uremic hyperplastic parathyroid glands, which may explain the lack of response to FGF23 in this tissue. In conclusion, in hyperparathyroidism secondary to renal failure, the parathyroid cells resist the inhibitory effects of FGF23, perhaps as a result of the low expression of FGF23 receptor 1 and Klotho in this condition.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20431039      PMCID: PMC3152229          DOI: 10.1681/ASN.2009040427

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  25 in total

1.  Regulation of fibroblast growth factor-23 signaling by klotho.

Authors:  Hiroshi Kurosu; Yasushi Ogawa; Masayoshi Miyoshi; Masaya Yamamoto; Animesh Nandi; Kevin P Rosenblatt; Michel G Baum; Susan Schiavi; Ming-Chang Hu; Orson W Moe; Makoto Kuro-o
Journal:  J Biol Chem       Date:  2006-01-25       Impact factor: 5.157

2.  Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo.

Authors:  Hitoshi Saito; Akira Maeda; Shu-Ichi Ohtomo; Michinori Hirata; Kenichiro Kusano; Shigeaki Kato; Etsuro Ogata; Hiroko Segawa; Ken-Ichi Miyamoto; Naoshi Fukushima
Journal:  J Biol Chem       Date:  2004-11-05       Impact factor: 5.157

3.  Klotho converts canonical FGF receptor into a specific receptor for FGF23.

Authors:  Itaru Urakawa; Yuji Yamazaki; Takashi Shimada; Kousuke Iijima; Hisashi Hasegawa; Katsuya Okawa; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Nature       Date:  2006-10-29       Impact factor: 49.962

4.  Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.

Authors:  Shohei Nakanishi; Junichiro James Kazama; Tomoko Nii-Kono; Kentaro Omori; Takeyoshi Yamashita; Seiji Fukumoto; Fumitake Gejyo; Takashi Shigematsu; Masafumi Fukagawa
Journal:  Kidney Int       Date:  2005-03       Impact factor: 10.612

5.  The parathyroid is a target organ for FGF23 in rats.

Authors:  Iddo Z Ben-Dov; Hillel Galitzer; Vardit Lavi-Moshayoff; Regina Goetz; Makoto Kuro-o; Moosa Mohammadi; Roy Sirkis; Tally Naveh-Many; Justin Silver
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

6.  Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients.

Authors:  Fumihiko Koiwa; Junichiro J Kazama; Akihide Tokumoto; Noritaka Onoda; Hitoshi Kato; Tomoyuki Okada; Tomoko Nii-Kono; Masafumi Fukagawa; Takashi Shigematsu
Journal:  Ther Apher Dial       Date:  2005-08       Impact factor: 1.762

7.  Type I membrane klotho expression is decreased and inversely correlated to serum calcium in primary hyperparathyroidism.

Authors:  Peyman Björklund; Tijana Krajisnik; Göran Akerström; Gunnar Westin; Tobias E Larsson
Journal:  J Clin Endocrinol Metab       Date:  2008-08-05       Impact factor: 5.958

8.  Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.

Authors:  Orlando M Gutiérrez; Michael Mannstadt; Tamara Isakova; Jose Alejandro Rauh-Hain; Hector Tamez; Anand Shah; Kelsey Smith; Hang Lee; Ravi Thadhani; Harald Jüppner; Myles Wolf
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

9.  Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells.

Authors:  Tijana Krajisnik; Peyman Björklund; Richard Marsell; Osten Ljunggren; Göran Akerström; Kenneth B Jonsson; Gunnar Westin; Tobias E Larsson
Journal:  J Endocrinol       Date:  2007-10       Impact factor: 4.286

10.  alpha-Klotho as a regulator of calcium homeostasis.

Authors:  Akihiro Imura; Yoshihito Tsuji; Miyahiko Murata; Ryota Maeda; Koji Kubota; Akiko Iwano; Chikashi Obuse; Kazuya Togashi; Makoto Tominaga; Naoko Kita; Ken-ichi Tomiyama; Junko Iijima; Yoko Nabeshima; Makio Fujioka; Ryo Asato; Shinzo Tanaka; Ken Kojima; Juichi Ito; Kazuhiko Nozaki; Nobuo Hashimoto; Tetsufumi Ito; Takeshi Nishio; Takashi Uchiyama; Toshihiko Fujimori; Yo-ichi Nabeshima
Journal:  Science       Date:  2007-06-15       Impact factor: 47.728

View more
  66 in total

Review 1.  Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.

Authors:  Marie Courbebaisse; Beate Lanske
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

Review 2.  FGF23 and PTH--double agents at the heart of CKD.

Authors:  Justin Silver; Mariano Rodriguez; Eduardo Slatopolsky
Journal:  Nephrol Dial Transplant       Date:  2012-03-23       Impact factor: 5.992

Review 3.  Bone Disease in CKD in Children.

Authors:  Fernando Santos; Lucas Díaz-Anadón; Flor A Ordóñez; Dieter Haffner
Journal:  Calcif Tissue Int       Date:  2021-01-16       Impact factor: 4.333

4.  Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.

Authors:  Stuart M Sprague; James B Wetmore; Konstantin Gurevich; Gerald Da Roza; John Buerkert; Maureen Reiner; William Goodman; Kerry Cooper
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-14       Impact factor: 8.237

5.  Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease.

Authors:  Sharon M Moe; Miriam P Zidehsarai; Mary A Chambers; Lisa A Jackman; J Scott Radcliffe; Laurie L Trevino; Susan E Donahue; John R Asplin
Journal:  Clin J Am Soc Nephrol       Date:  2010-12-23       Impact factor: 8.237

Review 6.  Diseases of the parathyroid gland in chronic kidney disease.

Authors:  Hirotaka Komaba; Takatoshi Kakuta; Masafumi Fukagawa
Journal:  Clin Exp Nephrol       Date:  2011-08-06       Impact factor: 2.801

Review 7.  Klotho and chronic kidney disease.

Authors:  Ming Chang Hu; Makoto Kuro-o; Orson W Moe
Journal:  Contrib Nephrol       Date:  2013-05-03       Impact factor: 1.580

8.  Prevalence of intracranial artery calcification in hemodialysis patients--a case-control study.

Authors:  Yuko Iwasa; Shigeru Otsubo; Kazuomi Nomoto; Naobumi Yashiro; Aiji Yajima; Naoki Kimata; Takashi Akiba; Kosaku Nitta
Journal:  Int Urol Nephrol       Date:  2011-07-08       Impact factor: 2.370

9.  Phosphorylation of Ribosomal Protein S6 Mediates Mammalian Target of Rapamycin Complex 1-Induced Parathyroid Cell Proliferation in Secondary Hyperparathyroidism.

Authors:  Oded Volovelsky; Gili Cohen; Ariel Kenig; Gilad Wasserman; Avigail Dreazen; Oded Meyuhas; Justin Silver; Tally Naveh-Many
Journal:  J Am Soc Nephrol       Date:  2015-08-17       Impact factor: 10.121

10.  Functional heterogeneity of osteocytes in FGF23 production: the possible involvement of DMP1 as a direct negative regulator.

Authors:  Ji-Won Lee; Akira Yamaguchi; Tadahiro Iimura
Journal:  Bonekey Rep       Date:  2014-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.